Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

The average one-year price target for Recursion Pharmaceuticals (NasdaqGS:RXRX) has been revised to $7.14 / share. This is an increase of 10.53% from the prior estimate of $6.46 dated December 3, 2025 ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...